RDUS - ラディウス・ヘルス (Radius Health Inc.) ラディウス・ヘルス

 RDUSのチャート


 RDUSの企業情報

symbol RDUS
会社名 Radius Health Inc (ラディウス・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ラジウス・ヘルス(Radius Health Inc)は生物医薬品企業である。同社は骨粗鬆症、腫瘍学および内分泌疾患の分野における治療法の開発に焦点を当てる。同社の治験薬候補であるTYMLOS(アバロパラチド-SC)注射は骨折リスクの高い骨粗鬆症を有する閉経後女性の治療のために開発される。同社の臨床パイプラインには骨粗鬆症に使用する可能性のある治験用アバロパラチド経皮パッチと、ホルモン駆動またはホルモン耐性乳がん、閉経後女性の血管運動症状の潜在的使用に関する治験薬elacestrant(RAD1901)を含まれる。RAD140は非ステロイド系の選択的アンドロゲン受容体モジュレーター(SARM)である。RAD140はホルモン受容体陽性乳癌の潜在的使用のために開発される。   ラディウス・ヘルスは、米国の婦人科領域に特化したバイオ医薬品会社。骨粗鬆症患者向け治療薬を開発するだけでなく、他の内分泌媒介性疾患に焦点を当て事業を展開。主要製品候補は、骨粗鬆症の治療のための骨同化皮下注射Abaloparatide-SC。臨床製品ポ―トフォリオとしては、経口薬で選択的エストロゲン受容体低下剤RAD1901がある。   Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
本社所在地 950 Winter Street Waltham MA 02451 USA
代表者氏名 Kurt C. Graves Kurt C. Graves
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-551-4000
設立年月日 39479
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 561人
url www.radiuspharm.com
nasdaq_url https://www.nasdaq.com/symbol/rdus
adr_tso
EBITDA EBITDA(百万ドル) -242.34700
終値(lastsale) 18.83
時価総額(marketcap) 856321647.65
時価総額 時価総額(百万ドル) 862.23360
売上高 売上高(百万ドル) 58.30800
企業価値(EV) 企業価値(EV)(百万ドル) 803.73660
当期純利益 当期純利益(百万ドル) -259.29700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Radius Health Inc revenues increased from $980K to $37.2M. Net loss increased 4% to $130.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 26% to $49.2M (expense) General and administrative increase of 10% to $96.6M (expense).

 RDUSのテクニカル分析


 RDUSのニュース

   Radius Health (RDUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  2020/04/30 16:34:13 Zacks Investment Research
Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Radius Health (RDUS) Down 33.3% Since Last Earnings Report: Can It Rebound?  2020/03/28 15:30:44 Zacks Investment Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Earnings Preview: Radius Health (RDUS) Q4 Earnings Expected to Decline  2020/02/20 17:31:48 Zacks Investment Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Radius Health Is in Oversold Territory: What???s Next?  2020/01/06 14:13:00 Zacks Investment Research
Radius Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Radius Health (RDUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  2020/04/30 16:34:13 Zacks Investment Research
Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Radius Health (RDUS) Down 33.3% Since Last Earnings Report: Can It Rebound?  2020/03/28 15:30:44 Zacks Investment Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Earnings Preview: Radius Health (RDUS) Q4 Earnings Expected to Decline  2020/02/20 17:31:48 Zacks Investment Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Radius Health Is in Oversold Territory: What???s Next?  2020/01/06 14:13:00 Zacks Investment Research
Radius Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Earnings Preview: Radius Health (RDUS) Q4 Earnings Expected to Decline  2020/02/20 17:31:48 Zacks Investment Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Radius Health Is in Oversold Territory: What???s Next?  2020/01/06 14:13:00 Zacks Investment Research
Radius Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Why Is Radius Health (RDUS) Down 6.9% Since Last Earnings Report?  2019/12/05 16:31:09 Zacks Investment Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Radius Health (NASDAQ:RDUS) Rating Reiterated by HC Wainwright  2019/11/12 03:24:13 Modern Readers
HC Wainwright reissued their hold rating on shares of Radius Health (NASDAQ:RDUS) in a report issued on Thursday morning, AnalystRatings.com reports. They currently have a $27.00 price objective on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on RDUS. BidaskClub upgraded Radius Health from a hold rating to a […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ラディウス・ヘルス RDUS Radius Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)